Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria

Lancet. 2004 Jan 24;363(9405):283-9. doi: 10.1016/S0140-6736(03)15386-X.

Abstract

Background: Pregnancy-associated malaria caused by Plasmodium falciparum adherence to chondroitin sulfate A in the placental intervillous space is a major cause of low birthweight and maternal anaemia in areas of endemic P falciparum transmission. Adhesion-blocking antibodies that specifically recognise parasite-encoded variant surface antigens (VSA) are associated with resistance to pregnancy-associated malaria. We looked for a possible relation between VSA-specific antibody concentrations, placental infection, and protection from low birthweight and maternal anaemia.

Methods: We used flow cytometry to measure VSA-specific IgG concentrations in plasma samples taken during child birth from 477 Kenyan women selected from a cohort of 910 women on the basis of HIV-1 status, gravidity, and placental histology. We measured VSA expressed by one placental P falciparum isolate and two isolates selected or not selected for chondroitin sulfate A adhesiveness in-vitro.

Findings: Concentrations of plasma IgG specific for VSA, expressed by chondroitin sulfate A-adhering parasites (VSA in pregnancy-associated malaria or vsa-pam), increased with gravidity and were associated with placental histological findings. Women with chronic pregnancy-associated malaria and low or absent VSA-PAM-specific IgG had lower haemoglobin values (reduced by 17 g/L; 95% CI 8.1-25.2) and delivered smaller babies (birthweight reduced by 0.26 kg; 0.10-0.55) than did corresponding women with high VSA-PAM-specific IgG. No such relation was shown for concentrations of IgG with specificity for non-pregnancy-associated malaria VSA.

Interpretation: VSA-PAM-specific IgG protects against low birthweight and maternal anaemia. Our data indicate an important mechanism of clinical protection against malaria and raise hope for the clinical effectiveness of a potential VSA-based vaccine against pregnancy-associated malaria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Protozoan / immunology
  • Antigens, Protozoan / immunology
  • Antigens, Surface / immunology*
  • Cell Adhesion / immunology
  • Chondroitin Sulfates / immunology
  • Erythrocytes / immunology
  • Erythrocytes / parasitology
  • Female
  • Flow Cytometry
  • Humans
  • Immunity, Innate / immunology*
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Infant, Low Birth Weight / immunology
  • Infant, Newborn
  • Malaria Vaccines
  • Malaria, Falciparum / immunology*
  • Placenta Diseases / immunology
  • Plasmodium falciparum / immunology
  • Plasmodium falciparum / isolation & purification
  • Pregnancy
  • Pregnancy Complications, Parasitic / blood
  • Pregnancy Complications, Parasitic / immunology*
  • Pregnancy Complications, Parasitic / parasitology

Substances

  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Antigens, Surface
  • Immunoglobulin G
  • Malaria Vaccines
  • Chondroitin Sulfates